1Sato Y,Nishikawa M,Shinkai H,et al.Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4- isopropylcyclohexyl)-carbonyl]- D-Phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals[].Diabetes Research and Clinical Practice.1991
2Horton ES,Clinkingbeard C,Gatlin M,et al.Nateglinide alone or in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes[].Diabetes Care.2000
3Shinkai H,Toi K,Kumashiro I,et al.N- acylphenylalanines and related compounds: a new class of oral hypoglycemic agents[].Journal of Medicinal Chemistry.1988
4Hollander PA,Schwartz SL,Gatlin MR,et al.Importance of early insulin secretion : Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes[].Diabetes Care.2001
5Hanefeld M,Bouter KP,Dickinson S,et al.Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia[].Diabetes Care.2000
6Ikenoue T.Hypoglycemic and insulinotropic effects of a novel oral antidiabetic agent, (- ) -N- [(trans- 4 - isopropylcyclohexyl) - carbonyl] - DPhenylalanine(A-4166)[].British Journal of Pharmacology.1997
7Fujitani S,Yada T.A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increase cytosolic free Ca2+ in rat pancreatic beta- cells by stimulating Ca2+ influx[].The Journal of Endocrinology.1994
8Keilson L,Mather S,Walter YH,et al.Synergistic effects of nateglinide and meal administration on insulin scretion in patients with type 2 diabetes mellitus[].The Journal of Clinical Endocrinology.2000
9Lider TR.FDA approves nateglinide for treatment of type 2 diabetes[].American Journal of Health System Pharmacy.2001
10Fujitani S,Okazaki K,Yada T.The ability of a new hypoglycemic agent , A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition[].British Journal of Pharmacology.1997
